Baxter Tumbles On $3.8 Billion Kidney Deal — Why Investors Expected More
Baxter stock tumbled Tuesday after the medtech company agreed to sell its kidney segment to Carlyle for $3.8 billion. The post Baxter Tumbles On $3.8 Billion Kidney Deal — Why Investors Expected More appeared first on Investor's Business Daily.
Baxter stock tumbled Tuesday after the medtech company agreed to sell its kidney segment to Carlyle for $3.8 billion.
The post Baxter Tumbles On $3.8 Billion Kidney Deal — Why Investors Expected More appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
